BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · IEX Real-Time Price · USD
26.19
+0.26 (1.00%)
At close: Jul 19, 2024, 4:00 PM
26.58
+0.39 (1.49%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $218.60M in the twelve months ending March 31, 2024, with 181.05% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $211.12M with 11,461.88% year-over-year growth. In the year 2023, BridgeBio Pharma had annual revenue of $9.30M.
Revenue (ttm)
$218.60M
Revenue Growth
+181.05%
P/S Ratio
22.42
Revenue / Employee
$397,449
Employees
550
Market Cap
4.90B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Select Medical Holdings | 6.79B |
| PACS Group | 3.34B |
| RadNet | 1.66B |
| Haemonetics | 1.31B |
| Merit Medical Systems | 1.28B |
| Apellis Pharmaceuticals | 524.07M |
| Doximity | 475.42M |
| TransMedics Group | 296.92M |
BBIO News
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO - GlobeNewsWire
- 9 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO - GlobeNewsWire
- 16 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BBIO - Accesswire
- 27 days ago - Levi & Korsinsky Reminds BridgeBio Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BBIO - Accesswire
- 4 weeks ago - Lost Money on BridgeBio Pharma, Inc.(BBIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Accesswire
- 4 weeks ago - BridgeBio Pharma, Inc. (BBIO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - Accesswire
- 4 weeks ago - BridgeBio Pharma, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BBIO - Accesswire